The present invention relates to compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with coronavirus infections. The compositions comprise therapeutically effective amounts of a TLR2 agonist. Certain embodiments specify that the TLR2 agonist is a pegylated, palmitoylated-cysteine compound of Formula (I), (VI), (VII) or (VIII).

The present invention relates to compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with coronavirus infections. The compositions comprise therapeutically effective amounts of a TLR2 agonist. Certain embodiments specify that the TLR2 agonist is a pegylated, palmitoylated-cysteine compound of Formula (I), (VI), (VII) or (VIII).

Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

The present disclosure relates to therapeutic compositions and therapies for use in the treatment of diseases and disorders of the eye. The present disclosure relates to curved, multilayer controlled-release ocular implant devices which include the therapeutic compositions of the present disclosure. The present disclosure related to methods for delivery of the therapeutic agents to the eye and the treatment of diseases and disorders of the eye.

The present disclosure relates to therapeutic compositions and therapies for use in the treatment of diseases and disorders of the eye. The present disclosure relates to curved, multilayer controlled-release ocular implant devices which include the therapeutic compositions of the present disclosure. The present disclosure related to methods for delivery of the therapeutic agents to the eye and the treatment of diseases and disorders of the eye.

The disclosure provides a method comprising administering HIF stabilizing small molecule drugs to premature infants, whose survival is dependent upon mechanical ventilation and/or supplemental oxygen, to counteract the pathological effects of hyperoxia on lung development. Data in a mouse model of hyperoxia-induced neonatal lung disease supports a treatment with a HIF stabilizer during high oxygen exposure protects the lung. HIF stabilizers can be administered via various routes, including in an aerosolized state using a ventilator, intravenous, intraperitoneal or subcutaneous injection.

The disclosure provides a method comprising administering HIF stabilizing small molecule drugs to premature infants, whose survival is dependent upon mechanical ventilation and/or supplemental oxygen, to counteract the pathological effects of hyperoxia on lung development. Data in a mouse model of hyperoxia-induced neonatal lung disease supports a treatment with a HIF stabilizer during high oxygen exposure protects the lung. HIF stabilizers can be administered via various routes, including in an aerosolized state using a ventilator, intravenous, intraperitoneal or subcutaneous injection.

The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapy for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with the activity of cathepsin S, cannabinoid receptors type 1, tachykinin receptors type 1 and 2, prokineticin receptors type 1 and 2, bradykinin receptors type 1, melanocortin receptors MC4R, serotonin receptors 5-HT2B and NB-kB signaling pathway, by using benzyl (2S)-2-[2-(4-hydroxyphenyl)acetamido]-3-phenylpropanoate compound. ##STR00001## The compound and pharmaceutically acceptable adducts, hydrates and solvates thereof are a cathepsin S inhibitor, cannabinoid receptor type 1 agonist, tachykinin receptor type 1 and 2 antagonist, prokineticin receptor type 1 and 2 antagonist, bradykinin receptor type 1 antagonist, melanocortin receptor MC4R antagonist, serotonin receptor 5-HT2B antagonist, and NB-kB signaling pathway inhibitor. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound according to the invention.

The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapy for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with the activity of cathepsin S, cannabinoid receptors type 1, tachykinin receptors type 1 and 2, prokineticin receptors type 1 and 2, bradykinin receptors type 1, melanocortin receptors MC4R, serotonin receptors 5-HT2B and NB-kB signaling pathway, by using benzyl (2S)-2-[2-(4-hydroxyphenyl)acetamido]-3-phenylpropanoate compound. ##STR00001## The compound and pharmaceutically acceptable adducts, hydrates and solvates thereof are a cathepsin S inhibitor, cannabinoid receptor type 1 agonist, tachykinin receptor type 1 and 2 antagonist, prokineticin receptor type 1 and 2 antagonist, bradykinin receptor type 1 antagonist, melanocortin receptor MC4R antagonist, serotonin receptor 5-HT2B antagonist, and NB-kB signaling pathway inhibitor. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound according to the invention.